Numerous other therapeutic strategies focused on p53 are under clinical investigation, including gene therapy, vaccines, synthetic small interfering RNA oligonucleotides, bispecific antibodies targeting mutant p53, targeted T cell receptor–T cell therapies and agents that exploit synthetic lethality in tumours harbouring TP53 mutations [122, 123]. Here, TP53 is linked to neoplasm.